Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
NextCure, Inc. is a clinical-stage biopharmaceutical company developing innovative cancer therapies, primarily antibody-drug conjugates (ADCs). Its lead candidate, LNCB74, targets B7-H4, a tumor-associated protein, for cancers like breast and ovarian. The company also explores non-oncology programs, collaborates with LigaChem and Yale, and focuses on advancing targeted biologics through research, development, and strategic partnerships.
This description was generated via AI from an annual report. Updated about 1 year ago.